PMID- 36291854
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221030
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 20
DP  - 2022 Oct 17
TI  - Understanding Mechanisms of RKIP Regulation to Improve the Development of New 
      Diagnostic Tools.
LID - 10.3390/cancers14205070 [doi]
LID - 5070
AB  - One of the most dangerous aspects of cancer cell biology is their ability to 
      grow, spread and form metastases in the main vital organs. The identification of 
      dysregulated markers that drive intracellular signalling involved in the 
      malignant transformation of neoplastic cells and the understanding of the 
      mechanisms that regulate these processes is undoubtedly a key objective for the 
      development of new and more targeted therapies. RAF-kinase inhibitor protein 
      (RKIP) is an endogenous tumour suppressor protein that affects tumour cell 
      survival, proliferation, and metastasis. RKIP might serve as an early tumour 
      biomarker since it exhibits significantly different expression levels in various 
      cancer histologies and it is often lost during metastatic progression. In this 
      review, we discuss the specific impact of transcriptional, post-transcriptional 
      and post-translational regulation of expression and activation/inhibition of RKIP 
      and focus on those tumours for which experimental data on all these factors are 
      available. In this way, we could select how these processes cooperate with RKIP 
      expression in (1) Lung cancer; (2) Colon cancer, (3) Breast cancer; (4) myeloid 
      neoplasm and Multiple Myeloma, (5) Melanoma and (6) clear cell Renal Cell 
      Carcinoma. Furthermore, since RKIP seems to be a key marker of the development of 
      several tumours and it may be assessed easily in various biological fluids, here 
      we discuss the potential role of RKIP dosing in more accessible biological 
      matrices other than tissues. Moreover, this objective may intercept the still 
      unmet need to identify new and more accurate markers for the early diagnosis and 
      prognosis of many tumours.
FAU - Papale, Massimo
AU  - Papale M
AD  - Unit of Clinical Pathology, Department of Laboratory Diagnostics, University 
      Hospital "Policlinico Foggia", 71122 Foggia, Italy.
FAU - Netti, Giuseppe Stefano
AU  - Netti GS
AUID- ORCID: 0000-0003-3495-2707
AD  - Unit of Clinical Pathology, Center for Molecular Medicine, Department of Medical 
      and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
AD  - Unit of Nephology, Dialysis and Transplantation, Advanced Research Center on 
      Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University 
      of Foggia, 71122 Foggia, Italy.
FAU - Stallone, Giovanni
AU  - Stallone G
AD  - Unit of Nephology, Dialysis and Transplantation, Advanced Research Center on 
      Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University 
      of Foggia, 71122 Foggia, Italy.
FAU - Ranieri, Elena
AU  - Ranieri E
AUID- ORCID: 0000-0002-4996-3938
AD  - Unit of Clinical Pathology, Center for Molecular Medicine, Department of Medical 
      and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
AD  - Unit of Nephology, Dialysis and Transplantation, Advanced Research Center on 
      Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University 
      of Foggia, 71122 Foggia, Italy.
LA  - eng
GR  - University Research Projects 2019 "PRA 2019" and 2021 "PRA 2021", both 
      granted to G.S.N./University of Foggia/
PT  - Journal Article
PT  - Review
DEP - 20221017
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9600137
OTO - NOTNLM
OT  - PhosphoRKIP
OT  - RKIP
OT  - biological fluids
OT  - biomarkers
OT  - cancer
OT  - tissue
COIS- Massimo Papale and Elena Ranieri are currently shareholders of FLUIDIA srl, a 
      biotech company that developed and patented a new method of RKIP/p-RKIP 
      measurement in biological samples. (Applicant FLUIDIA srl; Inventor: Massimo 
      Papale).
EDAT- 2022/10/28 06:00
MHDA- 2022/10/28 06:01
PMCR- 2022/10/17
CRDT- 2022/10/27 01:14
PHST- 2022/09/02 00:00 [received]
PHST- 2022/10/07 00:00 [revised]
PHST- 2022/10/14 00:00 [accepted]
PHST- 2022/10/27 01:14 [entrez]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/28 06:01 [medline]
PHST- 2022/10/17 00:00 [pmc-release]
AID - cancers14205070 [pii]
AID - cancers-14-05070 [pii]
AID - 10.3390/cancers14205070 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Oct 17;14(20):5070. doi: 10.3390/cancers14205070.